tbuckley/cabot-search huggingface dataset:
The need for Diagnosis-Related Group 471. Protection for clinical research
Authors: J. W. Yarbro
Journal: JAMA (1985)

TODAY we face a crisis in clinical research that demands that attention be directed to a problem that physicians have not had to worry about in the past: the impact of reimbursement for patient care on the progress of medical science. Until this year, the costs for patients involved in clinical trials were paid in two ways: the research costs of data collection and analysis, experimental drugs, and such were paid by research grants; the patient-care costs were paid by the patient or the insurance carrier. The advent of the prospective payment system and diagnosis-related group (DRG) reimbursement dramatically alters this system and changes the incentives. Under the DRG system, the hospital receives a fee fixed by diagnosis, and administrators are likely to show little enthusiasm for anything that increases the cost of care. Extra laboratory tests or x-ray films beyond a bare minimum will not be encouraged. The pattern
Value of Skin-Surface Glucose Test as Screening Procedure for Diabetes
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Activation of K+-Cl- cotransporters is involved in the increase in cell volume during alpha1-adrenergic agonist-stimulated hypertrophy in cardiac myocytes Tsuyoshi Kakita, Koji Hasagawa, Masatoshi Fujita, Kazuaki Hiki, Tetsuhiko Yanazume, Shigetake Sasayama. Department of Cardiovascular Medicine Graduate School of Medicine, Kyoto University, Kyoto, Japan, College of medical Technology, Kyoto University, Kyoto, Japan
Journal: Journal of the American College of Cardiology (2001)
HER2Δ16 expression in HER2-positive breast cancer.
Authors: Jocelyn Torres De Yao, Danyu Sun, Donna Galehouse, Scott Shorten, Nairmeen Haller, Esther Hoogland Rehmus
Journal: Journal of Clinical Oncology (2014)

e11599 Background: 89% of HER2 positive breast cancer with this mutation developing local lymph node positive disease progression. This is the first study characterizing and determining the prevalence of HER2Δ16 isoform in patients from a NAPBC accredited cancer center. Methods: 95 HER2 positive breast cancer tissue samples from 2002-2008 were obtained from Akron General Medical Center. Total RNA from cancer cells were isolated and RT-PCR was performed using primers to amplify the wild-type HER2 and HER2Δ16 isoform. DNA products from RT-PCR were then loaded in agarose gel electrophoresis with the HER2Δ16 isoform band being shorter compared to the wild type HER2. Results: Preliminary results from our ongoing study showed 39% (12 of 31) of our HER2 samples has HER2Δ16 isoform. Out of the 12 HER2Δ16 isoform samples, 17% are Stage I, 50% are Stage II, 25% are Stage III, and 8% are Stage IV breast cancer at diagnosis. Patient age ranges from 34 to 87 years old, with 50% of the HER2Δ16 isoform patients having lymph node positive disease at the time of diagnosis. This is in contrast to HER2 wild type patient for which 26% (5 of 19) are diagnosed with Stage I disease and 42% have lymph node positive disease at the time of diagnosis. Conclusions: Transgenic mice that overexpressed rat HER2 oncogene with small extracellular domain deletion promoted transforming activity of this protein. HER2Δ16 isoform is detected in 39% of HER2 positive breast cancer based on our preliminary results with 50% having lymph-node positive breast cancer on initial diagnosis. Immunohistochemistry and FISH could not distinguish the wild type HER2 from the HER2Δ16 isoform. Further study is recommended for possible prognosticating utility of HER2Δ16 isoform in breast cancer.
Commission hears various views about drug testing in prisons
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Geriatric Problems
Authors: R. Tepper
Journal: BMJ (1968)

Collapsin response mediator proteins (CRMPs) mediate growth cone collapse during development, but their roles in adult brains are not clear. Here we report the findings that the full-length CRMP-3 (p63) is a direct target of calpain that cleaves CRMP-3 at the N terminus (+76 amino acid). Interestingly, activated calpain in response to excitotoxicity <i>in vitro</i> and cerebral ischemia <i>in vivo</i> also cleaved CRMP-3, and the cleavage product of CRMP-3 (p54) underwent nuclear translocation during neuronal death. The expression of p54 was colocalized with the terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling-positive nuclei in glutamate-treated cerebellar granule neurons (CGNs) and in ischemic neurons located in the infarct core after focal cerebral ischemia, suggesting that p54 might be involved in neuronal death. Overexpression studies showed that p54, but not p63, caused death of human embryonic kidney cells and CGNs, whereas knock-down CRMP-3 expression by selective small interfering RNA protected neurons against glutamate toxicity. Collectively, these results reveal a novel role of CRMP-3 in that calpain cleavage of CRMP-3 and the subsequent nuclear translocation of the truncated CRMP-3 evokes neuronal death in response to excitotoxicity and cerebral ischemia. Our findings also establish a novel route of how calpain signals neuron death.
Drug Substitution—How to Turn Order Into Chaos
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Open-label, dose confirmation, and dosimetry study of interstitial <sup>131</sup>I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results.
Authors: W. R. Shapiro, K. Judy, S. J. Patel, R. A. Lustig, K. Spicer, S. Shen, J. Lai, J. Shan
Journal: Journal of Clinical Oncology (2010)

2039 Background: Interstitial 131I-chTNT-1/B MAb (Cotara) is a radioiodinated chimeric monoclonal antibody specific for DNA and histone H1 complex, which is exposed in the necrotic areas of gliomas. We are reporting on a dose confirmation and radiation dosimetry trial which examines safety and biodistribution of Cotara. Methods: Patients with recurrent GBM and clinical target volume of 5-60 cc were eligible. Cotara was infused via 2 interstitial catheters. Ten patients received a 3 mCi imaging dose of Cotara. Two to four weeks after imaging, patients were eligible to receive a therapy dose. Three cohorts consisting of 3-4 patients each received a therapy dose of 1.5, 2.0 or 2.5 mCi/cc. Dose escalation was permitted after all patients in a cohort had been observed for 6 weeks, and all treatment-related toxicities were ≤ grade 2. Biodistribution was determined using sequential whole body images and counting blood samples. Uptake and clearance of Cotara in tissues were quantified and radiation doses were determined based on medical internal radiation dose schema. Results: The most common AEs (≥ 25%) were: headaches, nausea, constipation, brain edema, incision site complications, seizures, hemiparesis, fatigue, hyperglycemia and hypertension. 13 serious adverse events (SAEs) were observed in 8 patients, 3 had drug-related SAEs at 1.5 mCi/cc (none of which were considered DLTs) and 1 had a drug related SAE at 2.5 mCi/cc. The administered therapeutic radiation dose ranged from 15-85 mCi and 1 dose-limiting toxicity (brain edema) was observed at 2.5 mCi/cc. Images acquired up to 168 hours post infusion demonstrated Cotara was concentrated only in tumor; minimal uptake of Cotara could be faintly visualized in stomach, heart, and thyroid only for some patients. Median tumor-to-body dose ratio was 719 (range 320-3,470). Conclusions: Cotara was well-tolerated, with a single DLT observed at the 2.5 mCi/cc dose level. Dosimetry assessments indicate that Cotara localized only in tumor with minimal systemic radiation exposure. These clinical and dosimetry findings support clinical trials of Cotara over 25 hrs via 2 interstitial catheters at or below 2.5 mCi/cc. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Peregrine Pharmaceuticals Peregrine Pharmaceuticals Peregrine Pharmaceuticals Peregrine Pharmaceuticals Peregrine Pharmaceuticals
Right lower quadrant pain in the teen-aged girl
Authors: E. Palmer
Journal: JAMA (1974)

YOU don't have to be in family practice long to realize that right lower quadrant pain in the teen-aged girl is a very common problem. You discover quickly, too, that there are no recent advances to help the clinician here, and that your consultants, medical and surgical, are likely to have widely divergent opinions in their diagnostic and therapeutic advice. Quite regularly this poses a difficult clinical problem. The diagnostic possibilities are many, the most common being acute appendicitis, acute gonorrheal pelvic peritonitis, granulomatous enterocolitis, acute mesenteric adenitis, cecal gas syndrome, irritable colon syndrome, and a constipation syndrome. Many experienced pediatricians would not agree with this list of diagnostic possibilities at all. They would say that by far the most common explanation for such pain among patients of this category is a quasimalingering form of emotional response to the superficial problems of growing up. Furthermore, if this is the working
NEONAX: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer—A phase II study of the AIO Pancreatic Cancer Group.
Authors: Thomas Jens Ettrich, Andreas W. Berger, Rainer Muche, Manfred P. Lutz, Nicole Prasnikar, Waldemar Uhl, Andrea Tannapfel, Volker Heinemann, Thomas Seufferlein
Journal: Journal of Clinical Oncology (2014)

TPS4158 Background: Resectable pancreatic cancer still has an unfavourable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Recently, two phase III trials demonstrated for the first time, a substantial improvement in overall response, PFS and OS in patients with metastatic pancreatic cancer compared to standard gemcitabine (FOLFIRINOX and nab-paclitaxel/gemcitabine). The combination of nab-paclitaxel/gemcitabine has a more favourable toxicity profile compared to the FOLFIRINOX protocol and appears applicable in a perioperative setting. Methods: NEONAX is a study for patients (to be enrolled: n=162) with resectable ductal adenocarcinoma of the pancreas ≤ T3 in two arms: Arm A (perioperative arm): 2 cycles nab-paclitaxel (125 mg/m2)/gemcitabine (1000 mg/m2, d1, 8 and 15 of an 28 day-cycle) - tumor surgery - 4 cycles nab-paclitaxel/gemcitabine, Arm B (adjuvant only arm): tumor surgery - 6 cycles nab-paclitaxel/gemcitabine. NEONAX is an interventional, prospective, randomized, controlled, open label, two sided phase II study with an unconnected analysis of the results in both experimental arms against a fixed survival probability (38% at 18 month with adjuvant gemcitabine). The randomization (1:1) is eminent to achieve two comparable patient groups. Primary objective is DFS at 18 months after randomization. Key secondary objectives are 3-year OS and DFS, progression during neoadjuvant therapy and QoL. In the perioperative group tumor tissue will be collected prior to and post-surgery and subjected to microdissection and exome sequencing of tumor tissue. Tumor regression will be assessed both in the perioperative and the adjuvant group, respectively. In addition, circulating tumor-DNA will be analyzed in patients with the best and the worst responses to the neoadjuvant treatment Start of trial will be in II/2014 in 20 high-volume centers for pancreatic surgery in Germany. Clinical trial information: NCT02047513.
PWE-034 The clinical and economic cost of delirium following surgical resection for oesophageal malignancy
Authors: S R Markar, I Smith, D Low
Journal: Gut (2012)

<h3>Introduction</h3> Delirium is an under-estimated and serious complication following major surgery, particularly in the elderly population. The aim of this study was to identify pre-operative risk factors for delirium following oesophagectomy for malignancy, and investigate its impact upon short and long-term outcome. <h3>Methods</h3> All patients undergoing oesophagectomy for cancer between 1991 and 2011 had information prospectively entered in an IRB-approved database. Patients were divided into two groups based upon the presence or absence of clinically-significant post-operative delirium, and were compared with respect to use of neoadjuvant therapy, medical co-morbidities, operative outcomes, post-operative complications, overall cost and survival. For the purposes of this study delirium was defined as an acute fluctuating confusional state that required intervention. <h3>Results</h3> 500 patients were included in this analysis; 46 (9.2%) patients with post-operative delirium and 454 patients without. In the delirium group, age was significantly increased (71±8.1 yrs vs 63±10.9 yrs) and BMI was reduced (25±4.2 vs 27±4.8 kg/m<sup>2</sup>). There were no significant differences in cardiac, pulmonary or renal co-morbidities, however ASA grade (2.8±0.4 vs 2.6±0.5) and Charlson Co-morbidity index (2.5±0.7 vs 2.3±0.6) were significantly increased in the delirium group. There were no significant differences between the groups in the use of neoadjuvant therapy. Analysis demonstrated that delirium was associated with a significantly longer hospital (14±7.5 vs 10.9±5.7 days) and ICU stay (3.6±3.8 vs 2.7±16.9 days). Furthermore post-operative delirium was associated with a significantly increased incidence of post-operative pneumonia (21.7% vs 7.9%), pneumothorax (10.9% vs 2.6%), re-intubation (10.9% vs 1.8%) and increased overall treatment costs ($28 223±13 018 vs $22 702±9689; p&lt;0.05). Age was the only pre-operative predictor of post-operative delirium in multivariate modelling (OR 1.08; 95% CI 1.04 to 1.12, p&lt;0.05). Patients were followed-up for an average of approximately 4 years. There was no significant difference between the groups in overall survival (1105±910 days vs 1273±1428; p=0.28). <h3>Conclusion</h3> This study demonstrates that delirium is a risk factor for complicated post-operative recovery and increased treatment costs following oesophagectomy, and furthermore that age is independently predictive of its development. Focused screening will allow targeted preventative strategies to be employed in the peri-operative period to reduce complications and cost associated with delirium. <h3>Competing interests</h3> None declared.
Editorial: Prinzmetal variant of angina pectoris
Authors: J. W. Linhart
Journal: JAMA (1974)

In 1959, Prinzmetal et al<sup>1</sup>described a variant of angina pectoris. Although it caused chest discomfort similar in quality and location to that described by Heberden, it differed in the following respects: (1) Chest pain began most commonly at rest or with ordinary activity (not with exertion), (2) prominent ST elevation occurred during episodes of chest pain and the electrocardiogram was typically normal in the absence of pain, (3) exercise tests were frequently negative, (4) there was single coronary artery disease with a focal lesion, (5) arrhythmias, commonly ventricular tachycardia or conduction disorders, or both, occurred during the pain, and (6) frequently, myocardial infarction ensued in the area of the heart corresponding to the ST segment elevation. Angina was rare after the myocardial infarction. Subsequent reports from other investigators confirmed and amplified these initial diagnostic features, eg, the cyclical nature of the pain; its frequent mimicry of coronary insufficiency
SALT AND HYPERTENSION
Authors: J.J. Brown, A.F. Lever, J.I.S. Robertson, P.F. Semple, R.F. Bing, A.M. Heagerty, J.D. Swales, H. Thurston, J.G.G. Ledingham, J.H. Laragh, L. Hansson, M.G. Nicholls, E.A. Espiner
Journal: The Lancet (1984)
Forensic Psychiatry
Authors: Sam Parker
Journal: JAMA (1980)

<h3>To the Editor.—</h3> The synopsis of forensic psychiatry inThe Journalwas excellent. The staff work was superior. However, I must respond to the quote from Emmanuel Tanay, MD, where he dismisses "dangerousness" as a legal and not a psychiatric concept. Since the beginnings of Western legal systems under kings, the state has always possessed and enforced its power to coerce the citizenry for the general health and welfare. Witness compulsory vaccination, education, and sanitation. It is not a legal concept that forces immigrants to undergo stringent physical examinations or overseas airplanes to be carefully washed and sprayed before departing for this country. The tacit and often expressed premise on which these police powers are based is the need to protect the people from "dangerous" illnesses. The recent flap over requiring all Amish people to be vaccinated is but the current illustration. Psychiatric illness is often no less "dangerous" than
Obituaries
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute Hemodynamic Effects of L-Alpha Methyldopa
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Textbook of Radiotherapy
Authors: Luther W. Brady
Journal: JAMA (1974)

In the second edition of the<i>Textbook of Radiotherapy</i>, the author has continued the presentation of the practices utilized in radiation therapy at the M. D. Anderson Hospital. This is being done within the context of a definite outlook, with the hope that more value would result. The author does not imply that this represents the only practice in radiation therapy, but he does develop the principles and practices currently utilized by his staff. There have been major changes in the exposition, related to the data accumulated from treatment in cancers of the head and neck, breast, and gynecologic tract. More emphasis has been placed on an integrated program for the management of cancer, utilizing not only radiation therapy but also surgical and chemotherapy techniques. Expanded sections have been added, relating to radiation physics, other high-energy photon beams as well as electron beams, and other specialty areas associated with cancer